TOKYO -- The Japanese government is on track to approve of Eli Lilly's popular obesity treatment Zepbound in the coming months, the head of the company told Nikkei Friday.
"It's under review in Japan, and we expect approval by the middle of next year," said Chair and CEO David Ricks.
